DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

BiDil: from another vantage point.

Author(s): Puckrein G

Affiliation(s): National Minority Health Month Foundation in Washington, DC, USA. gpuckrein@americanvisions.com

Publication date & source: 2006-09, Health Aff (Millwood)., 25(5):w368-74. Epub 2006 Aug 15.

Publication type: Research Support, Non-U.S. Gov't

In a recent Health Affairs Web Exclusive, Pamela Sankar and Jonathan Kahn argue against the Food and Drug Administration's approval of BiDil as a new drug for the treatment of heart failure in African Americans. Their paper questions the existence of disparities between African American and other heart-failure patients and the motivations of BiDil's developers and manufacturer. The disparities are confirmed and persistent, however, and BiDil's effectiveness is proven. If the authors' logic were to prevail, patients would be denied life-saving therapy. Continued investigation will likely narrow identification of patients who will benefit.

Page last updated: 2007-05-03

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017